A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients.

PubWeight™: 1.73‹?› | Rank: Top 3%

🔗 View Article (PMC 1422029)

Published in Ann Surg on September 01, 2001

Authors

R M Ghobrial1, R Steadman, J Gornbein, C Lassman, C D Holt, P Chen, D G Farmer, H Yersiz, N Danino, E Collisson, A Baquarizo, S S Han, S Saab, L I Goldstein, J A Donovan, K Esrason, R W Busuttil

Author Affiliations

1: Dumont-UCLA Transplant Center, Department of Surgery, UCLA School of Medicine, Los Angeles, California 90095, USA.

Articles citing this

Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med (2008) 6.67

In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrob Agents Chemother (2010) 2.28

Analysis of long-term outcomes of 3200 liver transplantations over two decades: a single-center experience. Ann Surg (2005) 1.73

Left-sided grafts for living-donor liver transplantation and split grafts for deceased-donor liver transplantation: their impact on long-term survival. Clin Res Hepatol Gastroenterol (2011) 1.63

Immunosuppression for liver transplantation in HCV-infected patients: mechanism-based principles. Liver Transpl (2005) 1.61

Survival after liver transplantation using hepatitis C virus-positive donor allografts: case-controlled analysis of the UNOS database. World J Surg (2011) 1.57

In vitro activity and preclinical profile of TMC435350, a potent hepatitis C virus protease inhibitor. Antimicrob Agents Chemother (2009) 1.50

Major challenges limiting liver transplantation in the United States. Am J Transplant (2011) 1.50

Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation (2004) 1.43

Pretransplant model to predict posttransplant survival in liver transplant patients. Ann Surg (2002) 1.22

Liver transplantation for fulminant hepatic failure: experience with more than 200 patients over a 17-year period. Ann Surg (2003) 1.15

Strategies to optimize the use of marginal donors in liver transplantation. World J Hepatol (2015) 0.95

New era of liver transplantation for hepatitis B: a 17-year single-center experience. Ann Surg (2002) 0.91

Managing pediatric hepatitis C: current and emerging treatment options. Ther Clin Risk Manag (2009) 0.90

In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob Agents Chemother (2013) 0.89

Antiviral therapy of chronic hepatitis C in patients with advanced liver disease and after liver transplantation. Med Microbiol Immunol (2009) 0.87

Management of Hepatitis C Post-liver Transplantation: a Comprehensive Review. J Clin Transl Hepatol (2015) 0.86

Identification of PTC725, an orally bioavailable small molecule that selectively targets the hepatitis C Virus NS4B protein. Antimicrob Agents Chemother (2013) 0.85

Donor graft steatosis influences immunity to hepatitis C virus and allograft outcome after liver transplantation. Transplantation (2011) 0.84

Utilization of expanded criteria donors in liver transplantation. Int J Organ Transplant Med (2013) 0.83

Retransplantation for graft failure in chronic hepatitis C infection: a good use of a scarce resource? World J Gastroenterol (2010) 0.83

SASLT practice guidelines: management of hepatitis C virus infection. Saudi J Gastroenterol (2012) 0.80

Changing pattern of donor selection criteria in deceased donor liver transplant: a review of literature. J Clin Exp Hepatol (2013) 0.80

The association of IL28B polymorphism and graft survival in patients with hepatitis C undergoing liver transplantation. PLoS One (2013) 0.80

TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage. Antimicrob Agents Chemother (2012) 0.80

Tacrolimus-based versus cyclosporine-based immunosuppression in hepatitis C virus-infected patients after liver transplantation: a meta-analysis and systematic review. PLoS One (2014) 0.80

Effect of nonviral factors on hepatitis C recurrence after liver transplantation. Ann Surg (2006) 0.80

Innate pathways of immune activation in transplantation. J Transplant (2010) 0.80

Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series. J Hepatocell Carcinoma (2014) 0.79

Antiviral activity and mode of action of TMC647078, a novel nucleoside inhibitor of the hepatitis C virus NS5B polymerase. Antimicrob Agents Chemother (2011) 0.79

Hepatitis C virus recurrence in living donor liver transplant recipients. Dig Dis Sci (2004) 0.79

Management of HCV infection and liver transplantation. Int J Med Sci (2006) 0.77

Live liver donors' risk thresholds: risking a life to save a life. HPB (Oxford) (2013) 0.77

Can we direct organ allocation based on predicted outcome? Hepatocellular carcinoma outside of UCSF criteria or retransplant? Langenbecks Arch Surg (2012) 0.77

Hepatitis B and Hepatitis C Reactivation in the Biologic Era. J Clin Transl Hepatol (2014) 0.76

Association of preoperative parameters with postoperative mortality and long-term survival after liver transplantation. Can J Surg (2011) 0.76

Hepatitis C and liver transplantation. Hippokratia (2009) 0.76

Survival benefits of interferon-based therapy in patients with recurrent hepatitis C after orthotopic liver transplantation. Braz J Med Biol Res (2017) 0.75

Predictive factors for survival and score application in liver retransplantation for hepatitis C recurrence. World J Gastroenterol (2016) 0.75

Hepatic preservation injury: severity of hepatitis C recurrence and survival after liver transplantation. Dig Dis Sci (2013) 0.75

Recurrent hepatitis C post-transplantation: where are we now and where do we go from here? A report from the Canadian transplant hepatology workshop. Can J Gastroenterol (2006) 0.75

Antihepatitis C virus therapy in liver transplanted patients. Ther Clin Risk Manag (2006) 0.75

Curing Hepatitis C in Liver Transplant Recipients Is Associated with Changes in Immunosuppressant Use. J Clin Transl Hepatol (2016) 0.75

Perioperative blood transfusion affects hepatitis C virus (HCV)-specific immune responses and outcome following liver transplantation in HCV-infected patients. HPB (Oxford) (2013) 0.75

Effectiveness of Ledipasvir/Sofosbuvir with/without Ribavarin in Liver Transplant Recipients with Hepatitis C. J Clin Transl Hepatol (2017) 0.75

Articles cited by this

Epidemiology of hepatitis C. Hepatology (1997) 4.90

Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med (1996) 4.10

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Selecting the donor liver: risk factors for poor function after orthotopic liver transplantation. Hepatology (1994) 2.73

Risk factors for primary dysfunction after liver transplantation--a multivariate analysis. Transplantation (1993) 2.20

Recurrent and acquired hepatitis C viral infection in liver transplant recipients. Gastroenterology (1992) 2.09

Predictors of patient and graft survival following liver transplantation for hepatitis C. Hepatology (1998) 1.95

Long-term survival after retransplantation of the liver. Ann Surg (1997) 1.91

Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol (1997) 1.91

A longitudinal analysis of hepatitis C virus replication following liver transplantation. Gastroenterology (1996) 1.65

Diagnostic tests for hepatitis C. Hepatology (1997) 1.58

Preoperative risk factor assessment in liver transplantation. Surgery (1992) 1.55

Serum hepatitis C RNA titers after liver transplantation are not correlated with immunosuppression or hepatitis. Transplantation (1996) 1.50

Reinfection of liver graft by hepatitis C virus after liver transplantation. J Clin Invest (1992) 1.45

Severe recurrent cholestatic hepatitis C following orthotopic liver transplantation. Hepatology (1996) 1.42

The use of marginal donors for liver transplantation. A retrospective study of 365 liver donors. Transplantation (1992) 1.41

The course of hepatitis C virus infection after liver transplantation. Hepatology (1994) 1.38

Quantitation of hepatitis C virus RNA in liver transplant recipients. Gastroenterology (1994) 1.37

Prognostic value of preoperatively obtained clinical and laboratory data in predicting survival following orthotopic liver transplantation. Hepatology (1986) 1.31

Hepatic Retransplantation--an analysis of risk factors associated with outcome. Transplantation (1996) 1.22

Long-term outcome of hepatitis C virus infection after liver transplantation. Hepatology (1997) 1.21

Predictors of survival after In vivo split liver transplantation: analysis of 110 consecutive patients. Ann Surg (2000) 1.21

The deleterious effect of donor high plasma sodium and extended preservation in liver transplantation. A multivariate analysis. Transplantation (1996) 1.17

Hepatitis C virus and organ transplantation. Transplantation (1996) 1.17

Severe or multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology (1995) 1.16

Timing and severity of initial hepatitis C recurrence as predictors of long-term liver allograft injury. Transplantation (1998) 1.04

Orthotopic liver transplantation for hepatitis C: outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg (1999) 1.01

Hepatitis C virus recurrence after liver transplantation. Gut (1999) 1.01

A prognostic model for the outcome of liver transplantation in patients with cholestatic liver disease. Hepatology (1997) 1.00

Multiple organ failure after liver transplantation. Crit Care Med (1995) 0.94

Clinical characteristics affecting the outcome of liver retransplantation. Transplantation (1997) 0.93

Demographic determinants of hepatitis C virus seroprevalence among blood donors. JAMA (1996) 0.93

Retransplantation for recurrent hepatitis C. Liver Transpl Surg (1997) 0.90

Risk factors for recurrence of hepatitis C after liver transplantation. Liver Transpl Surg (1998) 0.87

Graft loss following liver transplantation in patients with chronic hepatitis C. Transplantation (1996) 0.86

Clinical outcome of patients infected with hepatitis C virus infection on survival after primary liver transplantation under tacrolimus. Liver Transpl Surg (1998) 0.86

Recurrent hepatitis C after liver transplantation: clinical and therapeutical issues. J Viral Hepat (2000) 0.84

Recurrent hepatitis C virus hepatitis in liver transplant recipients receiving tacrolimus: association with rejection and increased immunosuppression after transplantation. Surgery (1996) 0.84

Retransplantation for recurrent hepatitis C following tacrolimus or cyclosporine immunosuppression. Transplant Proc (1998) 0.82

Recurrent hepatitis C after liver transplantation. J Med Virol (2000) 0.81

Use of anti-hepatitis C virus seropositive organs in liver transplantation. Transplant Proc (1995) 0.79

Articles by these authors

The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology (1994) 21.65

Experimental feasibility of multi-energy photon-counting K-edge imaging in pre-clinical computed tomography. Phys Med Biol (2008) 4.77

Rescue of signaling by a chimeric protein containing the cytoplasmic domain of CD45. Science (1993) 4.47

Inhibition of ICE family proteases by baculovirus antiapoptotic protein p35. Science (1995) 4.41

Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J Neurosci (2000) 4.14

Molecular mechanisms underlying chemopreventive activities of anti-inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-kappa B activation. Mutat Res (2001) 3.94

Surgical anatomy of the hepatic arteries in 1000 cases. Ann Surg (1994) 3.83

Bacteriologic and surgical determinants of survival in patients with mycotic aneurysms. J Vasc Surg (1984) 3.65

Dark is a Drosophila homologue of Apaf-1/CED-4 and functions in an evolutionarily conserved death pathway. Nat Cell Biol (1999) 3.45

Amanita poisoning: treatment and the role of liver transplantation. Am J Med (1989) 3.20

A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine (1998) 3.07

The spectrum of behavioral changes in Alzheimer's disease. Neurology (1996) 2.97

Effects of psychotherapy with children and adolescents revisited: a meta-analysis of treatment outcome studies. Psychol Bull (1995) 2.59

MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther (2008) 2.43

Association of primary sclerosing cholangitis with HLA-DRw52a. N Engl J Med (1990) 2.40

Upregulation of heme oxygenase-1 protects genetically fat Zucker rat livers from ischemia/reperfusion injury. J Clin Invest (1999) 2.29

Perforation of the gallbladder: a frequently mismanaged condition. Am J Surg (1979) 2.26

Bridging the gap between laboratory and clinic in child and adolescent psychotherapy. J Consult Clin Psychol (1995) 2.17

Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells. J Biol Chem (1998) 2.13

The group I strain of Streptococcus mutans, UA140, produces both the lantibiotic mutacin I and a nonlantibiotic bacteriocin, mutacin IV. Appl Environ Microbiol (2001) 2.11

Liver and intestine transplantation in the United States, 1997-2006. Am J Transplant (2008) 2.04

Adjuvant chemotherapy improves survival after liver transplantation for hepatocellular carcinoma. Ann Surg (1995) 2.03

Ten-year incidence of dementia in a rural elderly US community population: the MoVIES Project. Neurology (2000) 2.03

Mitochondria are impaired in the adipocytes of type 2 diabetic mice. Diabetologia (2006) 2.02

The association of hepatitis C virus infection and post-liver transplant diabetes: data from 17 000 HCV-infected transplant recipients. Aliment Pharmacol Ther (2014) 2.01

Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica (1997) 1.98

Treatment of necrotizing soft tissue infections. The need for a new approach. Am J Surg (1985) 1.97

Long-term survival after retransplantation of the liver. Ann Surg (1997) 1.91

Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol (1997) 1.91

Transient exposure to HIV-1 Tat protein results in cytokine production in macrophages and astrocytes. A hit and run phenomenon. J Biol Chem (1999) 1.90

Chk2 activation dependence on Nbs1 after DNA damage. Mol Cell Biol (2001) 1.85

Antibody responses to Bordetella pertussis antigens and clinical correlations in elderly community residents. Clin Infect Dis (2000) 1.85

The first 100 liver transplants at UCLA. Ann Surg (1987) 1.84

Mechanisms of GDF-5 action during skeletal development. Development (1999) 1.83

Parenteral nutrition is associated with intestinal morphologic and functional changes in humans. JPEN J Parenter Enteral Nutr (1996) 1.81

Ischemia and reperfusion injury in liver transplantation. Transplant Proc (2005) 1.77

RAM2, an essential gene of yeast, and RAM1 encode the two polypeptide components of the farnesyltransferase that prenylates a-factor and Ras proteins. Proc Natl Acad Sci U S A (1991) 1.74

Transfer RNA modification: influence on translational frameshifting and metabolism. FEBS Lett (1999) 1.73

Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis. Lancet (1972) 1.71

Liver ischemia and reperfusion injury: new insights into mechanisms of innate-adaptive immune-mediated tissue inflammation. Am J Transplant (2011) 1.71

Infections in liver transplant recipients. Clin Infect Dis (1995) 1.71

Distinct phenotypes distinguish the molecular classes of Angelman syndrome. J Med Genet (2001) 1.71

Vitronectin stabilizes thrombi and vessel occlusion but plays a dual role in platelet aggregation. J Thromb Haemost (2005) 1.70

Catheter-related infections associated with home parenteral nutrition and predictive factors for the need for catheter removal in their treatment. JPEN J Parenter Enteral Nutr (1994) 1.68

Clinical and economic outcomes of individuals with severe peptic ulcer hemorrhage and nonbleeding visible vessel: an analysis of two prospective clinical trials. Am J Gastroenterol (1998) 1.66

Purification of mutacin III from group III Streptococcus mutans UA787 and genetic analyses of mutacin III biosynthesis genes. Appl Environ Microbiol (1999) 1.66

Psychiatric co-morbidity is associated with increased risk of surgery in Crohn's disease. Aliment Pharmacol Ther (2013) 1.64

Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med (1999) 1.63

Correlation between donor age and the pattern of liver graft recovery after transplantation. Transplantation (1995) 1.63

Targeted deletion of HIF-1alpha gene in T cells prevents their inhibition in hypoxic inflamed tissues and improves septic mice survival. PLoS One (2007) 1.61

Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intravenous choline supplementation. Hepatology (1995) 1.60

The role of liver biopsy in evaluating acute allograft dysfunction following liver transplantation: a clinical histologic correlation of 34 liver transplants. Hum Pathol (1988) 1.60

Long-term results of pediatric liver transplantation: an analysis of 569 transplants. Ann Surg (1998) 1.59

Expression and function of the leucine zipper protein Par-4 in apoptosis. Mol Cell Biol (1997) 1.59

Defect in multiple cell cycle checkpoints in ataxia-telangiectasia postirradiation. J Biol Chem (1996) 1.59

Nephrotic syndrome after treatment with 5-aminosalicylic acid. Br Med J (Clin Res Ed) (1988) 1.59

Current treatment modalities for hepatocellular carcinoma. Ann Surg (1994) 1.59

Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res (2001) 1.59

EGF receptor signaling enhances in vivo invasiveness of DU-145 human prostate carcinoma cells. Clin Exp Metastasis (1996) 1.57

Functional analyses of the promoters in the lantibiotic mutacin II biosynthetic locus in Streptococcus mutans. Appl Environ Microbiol (1999) 1.55

Bacteriophage T4 RNA ligase is gene 63 product, the protein that promotes tail fiber attachment to the baseplate. Proc Natl Acad Sci U S A (1977) 1.54

Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease--the LDQOL 1.0. Am J Gastroenterol (2000) 1.53

Moxalactam therapy for bacterial infections. Arch Intern Med (1981) 1.53

Purification and biochemical characterization of mutacin I from the group I strain of Streptococcus mutans, CH43, and genetic analysis of mutacin I biosynthesis genes. Appl Environ Microbiol (2000) 1.53

Breast cancer. Cyr61 is overexpressed, estrogen-inducible, and associated with more advanced disease. J Biol Chem (2001) 1.52

COPD in Chinese nonsmokers. Eur Respir J (2009) 1.52

Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos (1997) 1.52

Major challenges limiting liver transplantation in the United States. Am J Transplant (2011) 1.50

Simultaneous liver-kidney transplantation summit: current state and future directions. Am J Transplant (2012) 1.50

Gene dose effect reveals no Gs-coupled A2A adenosine receptor reserve in murine T-lymphocytes: studies of cells from A2A-receptor-gene-deficient mice. Biochem J (2001) 1.49

The diagnosis and management of visceral artery aneurysms. Surgery (1980) 1.49

Altered cytochrome c display precedes apoptotic cell death in Drosophila. J Cell Biol (1999) 1.49

Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology (1998) 1.48

An essential role for the caspase dronc in developmentally programmed cell death in Drosophila. J Biol Chem (2000) 1.46

Virulence of Mycobacterium tuberculosis CDC1551 and H37Rv in rabbits evaluated by Lurie's pulmonary tubercle count method. Infect Immun (1999) 1.46

Plasmodium falciparum strains from Papua New Guinea: culture characteristics and drug sensitivity. Southeast Asian J Trop Med Public Health (1980) 1.46

Is liver transplantation justified for the treatment of hepatic malignancies? Arch Surg (1990) 1.45

Localization of a portion of extranuclear ATM to peroxisomes. J Biol Chem (1999) 1.44

Activation of the reaper gene during ectopic cell killing in Drosophila. Dev Biol (1996) 1.44

Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines. Cancer Res (2001) 1.44

A new hereditary cataract mouse with lens rupture. Lab Anim (1997) 1.44

Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology (2000) 1.44

Results of a multicenter trial comparing imipenem/cilastatin to tobramycin/clindamycin for intra-abdominal infections. Ann Surg (1990) 1.43

Heavy chain ferritin acts as an antiapoptotic gene that protects livers from ischemia reperfusion injury. FASEB J (2003) 1.42

Determination of the X(3872) meson quantum numbers. Phys Rev Lett (2013) 1.42

T-category reflects the histopathologic characteristics of gallbladder cancer. Eur J Surg Oncol (2012) 1.41

The adequacy of cytology and colposcopy in diagnosing cervical neoplasia in HIV-seropositive women. Gynecol Oncol (1994) 1.40

Randomized, double-blind trial of anidulafungin versus fluconazole for prophylaxis of invasive fungal infections in high-risk liver transplant recipients. Am J Transplant (2014) 1.40